Dysregulation of autoimmunity caused by silica exposure: Fas-mediated apoptosis in T lymphocytes derived from silicosis patients

Autoimmune Disorders: Symptoms, Diagnosis and Treatment

Volumn , Issue , 2011, Pages 293-302

  Hayashi, Hiroaki ^a   Nishimura, Yasumitsu ^a   Hyodo, Fuminori ^b   Maeda, Megumi ^a   Kumagai, Naoko ^a   Miura, Yoshie ^c   Kusaka, Masayasu ^d   Uragam, Kozo ^e   Otsuki, Takemi ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c Kawasaki College of Allied Health Professions   (Japan)

^d Kusaka Hospital   (Japan)

^e HInase Uragami Iin   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84863282826     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (40)

1. Uber, CL; McReynolds, RA. Immunotoxicology of silica. Crit Rev Toxicol., 1982, 10, 303-19.
2. Steenlandm, K; Goldsmith, DF. Silica exposure and autoimmune diseases. Am J Ind Med., 1995, 28, 603-8.
3. Shanklin, DR, Smalley, DL. The immunopathology of siliconosis. History, clinical presentation, and relation to silicosis and the chemistry of silicon and silicone. Immunol Res., 1998, 18, 125-73.
4. Iannello, S; Camuto, M; Cantarella, S; Cavaleri, A; Ferriero, P; Leanza, A; Milazzo, P; Belfiore, F. Rheumatoid syndrome associated with lung interstitial disorder in a dental technician exposed to ceramic silica dust. A case report and critical literature review. Clin Rheumatol., 2002, 21, 76-81.
5. Kroesen, S; Itin, PH; Hasler, P. Arthritis and interstitial granulomatous dermatitis (Ackerman syndrome) with pulmonary silicosis. Semin Arthritis Rheum., 2003, 32, 33440.
6. Israeli, E; Agmon-Levin, N; Blank, M; Shoenfeld, Y. Adjuvants and autoimmunity. Lupus., 2009, 18, 1217-25.
7. Reyes, H; Ojo-Amaize, EA; Peter, JB. Silicates, silicones and autoimmunity. Isr J Med Sci. 1997, 33, 39-42.
8. Edelman, DA; Grant, S; van Os, WA. Autoimmune disease following the use of silicone gel-filled breast implants: a review of the clinical literature. Semin Arthritis Rheum., 1994, 24, 183-9.
9. Peters, W. Silicone breast implants and autoimmune connective tissue disease. Ann Plast Surg., 1995, 34, 103-9.
10. Mayes, MD. Epidemiologic studies of environmental agents and systemic autoimmune diseases. Environ Health Perspect., 1999, 107S5, 743-8.
11. Bar-Meir, E; Eherenfeld, M; Shoenfeld, Y. Silicone gel breast implants and connective tissue disease--a comprehensive review. Autoimmunity. 2003, 36, 193-7.
12. Hölmich, LR; Lipworth, L; McLaughlin, JK; Friis, S. Breast implant rupture and connective tissue disease: a review of the literature. Plast Reconstr Surg. 2007, 120, 62S-69S.
13. Sakaguchi, S; Sakaguchi, N; Shimizu, J; Yamazaki, S; Sakihama, T; Itoh, M; Kuniyasu, Y; Nomura, T; Toda, M; Takahashi, T. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev. 2001, 182, 18-32.
14. Sakaguchi, S. Immunologic tolerance maintained by regulatory T cells: implications for autoimmunity, tumor immunity and transplantation tolerance. Vox Sang. 2002, 83S1, 151-3.
15. Sakaguchi, S; Takahashi, T; Yamazaki, S; Kuniyasu, Y; Itoh, M; Sakaguchi, N; Shimizu, J. Immunologic self tolerance maintained by T-cell-mediated control of self-reactive T cells: implications for autoimmunity and tumor immunity. Microbes Infect. 2001, 3, 911-8.
16. Hori, S; Takahashi, T; Sakaguchi, S. Control of autoimmunity by naturally arising regulatory CD4+ T cells. Adv Immunol. 2003, 81, 331-71.
17. Takahashi, T; Sakaguchi, S. The role of regulatory T cells in controlling immunologic self-tolerance. Int Rev Cytol. 2003, 225, 1-32.
18. Sakaguchi, S. Animal models of autoimmunity and their relevance to human diseases. Curr Opin Immunol. 2000, 12, 684-90.
19. Guidelines for the Use of the ILO International Classification of Radiographs of Pneumoconioses, Revised Edition 2000, ILO (International Labour Organization), Geneva, Switzerland.
20. Strasser, A; Jost, PJ; Nagata, S. The many roles of FAS receptor signaling in the immune system. Immunity. 2009, 30, 180-92.
21. Lettau, M; Paulsen, M; Kabelitz, D; Janssen, O. Storage, expression and function of Fas ligand, the key death factor of immune cells. CurrMed Chem. 2008, 15, 1684-96.
22. Poppema, S; Maggio, E; van den Berg, A. Development of lymphoma in Autoimmune Lymphoproliferative Syndrome (ALPS) and its relationship to Fas gene mutations. Leuk Lymphoma. 2004, 45, 423-31.
23. Li-Weber, M; Krammer, PH. Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system. Semin Immunol. 2003, 15, 145-57.
24. Curtin, JF; Cotter, TG. Live and let die: regulatory mechanisms in Fas-mediated apoptosis. Cell Signal. 2003, 15, :983-92.
25. Krueger, A; Fas, SC; Baumann, S; Krammer, PH. The role of CD95 in the regulation of peripheral T-cell apoptosis. Immunol Rev. 2003, 193, 58-69.
26. Dianzani, U; Chiocchetti, A; Ramenghi, U. Role of inherited defects decreasing Fas function in autoimmunity. Life Sci. 2003, 72, 2803-24.
27. Zhan, HG; Mountz, JD; Fleck, M; Zhou, T; Hsu, HC. Specific deletion of autoreactive T cells by adenovirus-transfected, Fas ligand-producing antigen-presenting cells. Immunol Res. 2002, 26, 235-46.
28. Yonehara, S. Death receptor Fas and autoimmune disease: from the original generation to therapeutic application of agonistic anti-Fas monoclonal antibody. Cytokine Growth Factor Rev. 2002, 13, 393-402.
29. Fleisher, TA; Straus, SE; Bleesing, JJ. A genetic disorder of lymphocyte apoptosis involving the fas pathway: the autoimmune lymphoproliferative syndrome. Curr Allergy Asthma Rep. 2001, 1, 534-40.
30. Tomokuni, A; Aikoh, T; Matsuki, T; Isozaki, Y Otsuki, T Kita, S; Ueki, H; Kusaka, M; Kishimoto, T Ueki, A. Elevated soluble Fas/APO-1 (CD95) levels in silicosis patients without clinical symptoms of autoimmune diseases or malignant tumours. Clin Exp Immunol. 1997, 110, 303-9.
31. Otsuki, T; Sakaguchi, H; Tomokuni, A; Aikoh, T; Matsuki, T; Kawakami, Y; Kusaka, M; Ueki, H; Kita, S; Ueki, A. Soluble Fas mRNA is dominantly expressed in cases with silicosis. Immunology. 1998, 94, 258-62.
32. Otsuki T, Tomokuni A, Sakaguchi H, Aikoh T, Matsuki T, Isozaki Y, Hyodoh F, Ueki H, Kusaka M, Kita S, Ueki A. Over-expression of the decoy receptor 3 (DcR3) gene in peripheral blood mononuclear cells (PBMC) derived from silicosis patients. Clin Exp Immunol. 2000 Feb;119(2):323-7.
33. Otsuki, T; Sakaguchi, H; Tomokuni, A; Aikoh, T; Matsuki, T; Isozaki, Y; Hyodoh, F; Kawakami, Y; Kusaka, M; Kita, S; Ueki, A. Detection of alternatively spliced variant messages of Fas gene and mutational screening of Fas and Fas ligand coding regions in peripheral blood mononuclear cells derived from silicosis patients. Immunol Lett. 2000, 72, 137-43.
34. Otsuki, T: Miura, Y; Nishimura, Y; Hyodoh, F; Takata, A; Kusaka, M; Katsuyama, H; Tomita, M; Ueki, A; Kishimoto T. Alterations of Fas and Fas-related molecules in patients with silicosis. Exp Biol Med (Maywood). 2006, 231, 522-33.
35. Otsuki, T; Tomokuni, A; Sakaguchi, H; Hyodoh, F; Kusaka, M; Ueki, A. Reduced expression of the inhibitory genes for Fas-mediated apoptosis in silicosis patients. J Occup Health.2000, 42, 163-8.
36. Guo, Z-Q; Otsuki, T; Shimizu, T; Tachiyama, S; Sakaguchi, H; Isozaki, Y; Tomokuni, T; Hyodoh, F; Kusaka, M; Ueki, A. Reduced expression of survivin gene in PBMC from silicosis patients. Kawasaki Med J.2001, 27, 75-81.
37. Takata-Tomokuni, A; Ueki, A; Shiwa, M; Isozaki, Y; Hatayama, T; Katsuyama, H; Hyodoh, F; Fujimoto, W; Ueki, H; Kusaka, M; Arikuni, H; Otsuki, T. Detection, epitope-mapping and function of anti-Fas autoantibody in patients with silicosis. Immunology. 2005, 116, 21-9.
38. Wu, P; Miura, Y; Hyodoh, F; Nishimura, Y; Hatayama, T; Hatada, S; Sakaguchi, H; Kusaka, M; Katsuyama, H; Tomita, M; Otsuki, T. Reduced function of CD4+25+ regulatory T cell fraction in silicosis patients. Int JImmunopathol Pharmacol. 2006, 19, 357-68.
39. Wu, P; Hyodoh, F; Hatayama, T; Sakaguchi, H; Hatada, S; Miura, Y; Takata-Tomokuni, A; Katsuyama, H; Otsuki, T. Induction of CD69 antigen expression in peripheral blood mononuclear cells on exposure to silica, but not by asbestos/chrysotile-A. Immunol Lett. 2005, 98, 145-52.
40. Hayashi, H; Nishimura, Y; Maeda, M; Murakami, S; Kumagai, N; Chen, Y; Kusaka, M; Uragami, K; Fujimoto, W; Otsuki, T. Is soluble CD40 ligand an indicator of immunopathological disturbance in silicosis patients? Kawasaki Med J. 2009, 35, 129-138.